The funding will be used to advance the company’s new vaccine process development lines. Credit: Virica Biotech.

Canadian biotechnology company Virica Biotech has secured a grant from the Ontario provincial government to expand its domestic vaccine manufacturing capacity.

The $790,000 funding has been provided through the government’s Ontario Together Fund (OTF), created to boost Ontario’s healthcare sector, Covid-19 response and pandemic preparedness.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Virica will use the proceeds from the grant to expand its bioprocessing facilities and increase its capacity to scale up viral medicines and vaccine production.

The expansion project aims to advance new vaccine process development lines and increase the company’s bioprocessing capacity to meet customer demand for viral medicines.

It also aims to support the preparedness of the province for future public health emergencies by developing an off-the-shelf viral enhancement kit, expected to considerably amplify vaccine production capacity.

Virica Biotech CEO Dr Jean Simon Diallo stated: “Ontario Together funding is a boost to Virica’s continued growth.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our product line of viral enhancers enables us to seize the massive opportunity to reduce bioprocessing bottlenecks for viral medicine manufacturers and increase manufacturing yields and quality of essential viral-based therapies and vaccines.”

The company develops viral enhancers that support the production of viral medicines, facilitating the economical deployment of developers’ products at scale.

Virica secured $400,000 in funding from Innovation, Science and Economic Development Canada in 2022.

In May 2021, the company launched its first process innovation facility, along with the University of Ottawa Heart Institute and Ottawa Health Innovation Hub.